As of early 2026, the FDA has fully implemented its roadmap transitioning toward New Approach Methodologies (NAMs), such as organ-on-a-chip and in silico (AI) modeling.
While this reduces the ethical burden of animal testing, it places an immense reproducibility burden on biochemists. We are moving from observing a living animal to trust-coding an AI "Digital Twin."
For Discussion: Does a "digital twin" or a microfluidic chip truly capture the systemic complexity of human metabolism, or are we trading biological accuracy for regulatory speed? As future researchers, would you trust a life-saving drug that had never been tested in a complex, multi-organ living system?
